Abstract
Botulinum toxin, one of the world’s most deadly poisons, has become an extremely important pharmaceutical over the past 35+ years with a plethora of on-label and off-label uses. Chronic migraine sufferers now have another means of controlling their debilitating migraine pain. Understanding the toxin, its pharmacology, mechanism of action, how it is used, and how to avoid and treat adverse events is critical for any clinician to know that incorporates this agent into their practice. Of particular importance is an awareness of the on-label and off-label injection protocols to be able to use this product in a safe and effective manner.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kerner J. Neue Beobachtungen über die in Württemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuss geräucherter Würste. Tübingen: Osiander; 1820.
Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart, Tübingen: Cotta; 1822.
Dolman CE. Botulism as a world health problem. In: Lewis KH, Kassel K Jr, editors. Botulism. Cincinnati: U.S: Public Health Service; 1964.
Van Ermengem E. Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskr. 1897;26:1–56.
Lamanna C, McElroy OE, Eklund HW. The purification and crystallization of Clostridium botulinum Type A toxin. Science. 1946;103:613–4.
Brooks VB. The action of botulinum toxin on motor-nerve filaments. J Physiol. 1954;123(3):501–15. PMCID: PMC1366222.
Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924–7.
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17(1):21–5.
Scott AB. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. Am Acad Ophthalmol. 1989;Suppl:37–41. PMCID 2779991.
Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Ans Am Ophthalmol Soc. 1981;79:734–70. PMCID: PMC1312202.
Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. Botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21. doi:10.1111/j.1524-4725.1992.tb03295.x.
http://www.nytimes.com/1997/12/14/style/pulse-drought-over-botox-is-back.html.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm175013.htm. FDA Press Announcement. 3 Aug 2009.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm. FDA Press Announcement. 2010.
Hexsel DM, De Almeida AT, Rutowitsch M, De Castro IA, Silveira VL, Gobatto DO, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29(5):523–29; discussion 529.
Hexsel D, Rutowitsch MS, de Castro LC, do Prado DZ, Lima MM. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35(6):933–39; discussion 940. doi:10.1111/j.1524-4725.2009.01158.x.
McCaig LF, Burt CW. National hospital ambulatory medical care survey: 2001 emergency department summary. Adv Data. 2003;335:1–29.
McCaig LF, Burt CW. National hospital ambulatory medical care survey: 1999 emergency department summary. Adv Data. 2001;320:1–34.
Goldberg LD. The cost of migraine and its treatment. Am J Manage Care. 2005;11:S62–7.
Focus on migraine management: appropriate use of triptans. Drug Therapy Council Newsletter; 2002.
Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443–54.
Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalagia. Oxford, England, UK: Blackwell Publishing. 24 Suppl 1:1–160.
Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40(6):445–50.
Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123(6):669–76.
Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache. 2003;43(8):853–60.
Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalgia. 2004;24(1):60–5. doi:10.1111/j.1468-2982.2004.00641.x.
Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293–307.
Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80(9):1126–37.
Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005;45(4):315–24.
Guyuron B, Varghai A, Michelow BJ, Thomas T, Davis J. Corrugator supercilii muscle resection and migraine headaches. Plast Reconstr Surg. 2000;106(2):429–34; discussion 435–437.
Guyuron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plast Reconstr Surg. 2002;109(7):2183–9.
Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112 Suppl 5:171S–173S; discussion 174S-176S.
Mosser SW, Guyuron B, Janis JE, Rohrich RJ. The anatomy of the greater occipital nerve: implications for the etiology of migraine headaches. Plast Reconstr Surg. 2004;113(2):693–7; discussion 698–700.
Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg. 2005;115(1):1–9.
Guyuron B, Kriegler JS, Davis J, Amini SB. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2011;127(2):603–8. doi:10.1097/PRS.0b013e3181fed456.
Janis JE, Hatef DA, Ducic I, Reece EM, Hamawy AH, Becker S, Guyuron B. The anatomy of the greater occipital nerve: Part II. Compression point topography. Plast Reconstr Surg. 2010;126(5):1563–1572. doi:10.1097/PRS.0b013e3181ef7f0c.
Welch KM. Neurology. Contemporary concepts of migraine pathogenesis. 2003;61 (8 Suppl 4):S2–8. Review.
Lew M. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002;18(6):S142–6.
Novak VJ, Makek M. Pathogenesis and surgical treatment of migraine and neurovascular headaches with rhinogenic trigger. Head Neck. 1992;14(6):467–72.
Goadsby PJ. Pathophysiology of headache. In: Silberstein SD, Lipton RB, Solomon S, editors. Wolff’s headache and other head pain. 7th ed. Oxford, England: Oxford University Press; 2001. p. 57–72.
May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19(2):115–27.
Edvinsson L, Brodin E, Jansen I, Uddman R. Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. Regul Peptides. 1998;20(3):181–97.
Goadsby BT. Goadsby. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain. 2002;125:1496–509.
Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18(6):S125–32.
Bentsianov B, Zalvan C, Blitzer A. Noncosmetic uses of botulinum toxin. Clin Dermatol. 2004;22(1):82–8.
Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002;6:460–9.
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicol. 2005;26:785–93.
Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18. doi:10.1111/j.1526-4610.2010.01766.x.
Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology;77(15):1465–72. doi:10.1212/WNL.0b013e318232ab65.
Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296(20):2476–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Stepnick, D. (2017). Botulinum Toxin for Migraine Headaches. In: Mehle, M. (eds) Sinus Headache, Migraine, and the Otolaryngologist. Springer, Cham. https://doi.org/10.1007/978-3-319-50376-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-50376-9_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-50375-2
Online ISBN: 978-3-319-50376-9
eBook Packages: MedicineMedicine (R0)